Skip to main content
placeholder image

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

Journal Article


Abstract


Publication Date


  • 2011

Citation


  • Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., . . . Rothenberg, P. (2011). Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. DIABETES OBESITY & METABOLISM, 13(7), 669-672. doi:10.1111/j.1463-1326.2011.01406.x

Number Of Pages


  • 4

Start Page


  • 669

End Page


  • 672

Volume


  • 13

Issue


  • 7

Abstract


Publication Date


  • 2011

Citation


  • Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., . . . Rothenberg, P. (2011). Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. DIABETES OBESITY & METABOLISM, 13(7), 669-672. doi:10.1111/j.1463-1326.2011.01406.x

Number Of Pages


  • 4

Start Page


  • 669

End Page


  • 672

Volume


  • 13

Issue


  • 7